Esomeprazole
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Esomeprazole: From Gastroesophageal Reflux Disease to Duodenogastric Reflux
One-Sentence Summary
Esomeprazole is a proton pump inhibitor (PPI) generally used for acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and peptic ulcer disease. The TxGNN model predicts it may also be effective for Duodenogastric Reflux, but this specific prediction is currently supported by only 1 general review article and no dedicated clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on record in the evidence pack (drug currently not marketed in this jurisdiction); esomeprazole is generally used as a proton pump inhibitor for GERD, erosive esophagitis, and peptic ulcer disease |
| Predicted New Indication | Duodenogastric Reflux |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L4 (indirect/mechanistic evidence only — no trials or systematic reviews specific to this indication) |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, esomeprazole is the S-isomer of omeprazole and works as a proton pump inhibitor, irreversibly blocking the H+/K+-ATPase in gastric parietal cells to suppress gastric acid secretion. It is a well-established treatment for acid-related conditions including GERD, erosive esophagitis, peptic ulcer disease, and H. pylori-associated ulcer disease.
Duodenogastric reflux involves retrograde flow of duodenal contents (bile, pancreatic secretions) into the stomach, which is often accompanied by, or clinically overlaps with, acid-related mucosal injury. Because PPIs reduce gastric acidity and are already used adjunctively in reflux-related conditions, there is a plausible mechanistic rationale for exploring esomeprazole in this setting — acid suppression may reduce the combined acid-bile injury pattern seen in duodenogastric reflux, even though bile reflux itself is not directly acid-mediated.
At present, this rationale is inferred from esomeprazole’s general PPI pharmacology rather than from any study conducted specifically in duodenogastric reflux patients, which limits confidence in the mechanistic link.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18679668 | 2008 | Review | European Journal of Clinical Pharmacology | General review of PPI clinical use and pharmacokinetics; PPIs (including esomeprazole) are noted as first-choice therapy for peptic ulcer, H. pylori infection, GERD, NSAID-induced GI lesions, and Zollinger-Ellison syndrome — does not address duodenogastric reflux specifically |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but the supporting evidence for duodenogastric reflux specifically consists of a single general PPI review with no direct clinical trials, observational studies, or mechanism-specific data. Combined with missing MOA and safety/label data, the evidence base is currently too thin to proceed.
To proceed, the following is needed:
- TFDA/EU label warnings and contraindications (blocking data gap — required for S1 safety screening)
- Confirmed mechanism of action data from DrugBank
- Direct clinical or preclinical evidence linking esomeprazole to duodenogastric reflux specifically
- Confirmation of EU marketing authorization status, since the drug is currently recorded as not marketed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.